Details of Drug Off-Target (DOT)

General Information of Drug Off-Target (DOT) (ID: OT2S0GK8)

• DOT Name: Golgin subfamily B member 1 (GOLGB1)
• Synonyms: 372 kDa Golgi complex-associated protein; GCP372; Giantin; Macrogolgin
• Gene Name: GOLGB1
• Related Disease:
  Nephropathy
  Non-insulin dependent diabetes
  Advanced cancer
  Arteriosclerosis
  Atherosclerosis
  Cardiac failure
  Congestive heart failure
  HIV infectious disease
  Morquio syndrome
  Neoplasm
  Obesity
  Osteochondrodysplasia
  Red-green color blindness
  Gingivitis
  Hepatocellular carcinoma
  Stroke
  Cleft palate
  Emery-Dreifuss muscular dystrophy
  Isolated cleft palate
• UniProt ID: GOGB1_HUMAN
• Sequence:
  MLSRLSGLANVVLHELSGDDDTDQNMRAPLDPELHQESDMEFNNTTQEDVQERLAYAEQL
  VVELKDIIRQKDVQLQQKDEALQEERKAADNKIKKLKLHAKAKLTSLNKYIEEMKAQGGT
  VLPTEPQSEEQLSKHDKSSTEEEMEIEKIKHKLQEKEELISTLQAQLTQAQAEQPAQSST
  EMEEFVMMKQQLQEKEEFISTLQAQLSQTQAEQAAQQVVREKDARFETQVRLHEDELLQL
  VTQADVETEMQQKLRVLQRKLEEHEESLVGRAQVVDLLQQELTAAEQRNQILSQQLQQME
  AEHNTLRNTVETEREESKILLEKMELEVAERKLSFHNLQEEMHHLLEQFEQAGQAQAELE
  SRYSALEQKHKAEMEEKTSHILSLQKTGQELQSACDALKDQNSKLLQDKNEQAVQSAQTI
  QQLEDQLQQKSKEISQFLNRLPLQQHETASQTSFPDVYNEGTQAVTEENIASLQKRVVEL
  ENEKGALLLSSIELEELKAENEKLSSQITLLEAQNRTGEADREVSEISIVDIANKRSSSA
  EESGQDVLENTFSQKHKELSVLLLEMKEAQEEIAFLKLQLQGKRAEEADHEVLDQKEMKQ
  MEGEGIAPIKMKVFLEDTGQDFPLMPNEESSLPAVEKEQASTEHQSRTSEEISLNDAGVE
  LKSTKQDGDKSLSAVPDIGQCHQDELERLKSQILELELNFHKAQEIYEKNLDEKAKEISN
  LNQLIEEFKKNADNNSSAFTALSEERDQLLSQVKELSMVTELRAQVKQLEMNLAEAERQR
  RLDYESQTAHDNLLTEQIHSLSIEAKSKDVKIEVLQNELDDVQLQFSEQSTLIRSLQSQL
  QNKESEVLEGAERVRHISSKVEELSQALSQKELEITKMDQLLLEKKRDVETLQQTIEEKD
  QQVTEISFSMTEKMVQLNEEKFSLGVEIKTLKEQLNLLSRAEEAKKEQVEEDNEVSSGLK
  QNYDEMSPAGQISKEELQHEFDLLKKENEQRKRKLQAALINRKELLQRVSRLEEELANLK
  DESKKEIPLSETERGEVEEDKENKEYSEKCVTSKCQEIEIYLKQTISEKEVELQHIRKDL
  EEKLAAEEQFQALVKQMNQTLQDKTNQIDLLQAEISENQAIIQKLITSNTDASDGDSVAL
  VKETVVISPPCTGSSEHWKPELEEKILALEKEKEQLQKKLQEALTSRKAILKKAQEKERH
  LREELKQQKDDYNRLQEQFDEQSKENENIGDQLRQLQIQVRESIDGKLPSTDQQESCSST
  PGLEEPLFKATEQHHTQPVLESNLCPDWPSHSEDASALQGGTSVAQIKAQLKEIEAEKVE
  LELKVSSTTSELTKKSEEVFQLQEQINKQGLEIESLKTVSHEAEVHAESLQQKLESSQLQ
  IAGLEHLRELQPKLDELQKLISKKEEDVSYLSGQLSEKEAALTKIQTEIIEQEDLIKALH
  TQLEMQAKEHDERIKQLQVELCEMKQKPEEIGEESRAKQQIQRKLQAALISRKEALKENK
  SLQEELSLARGTIERLTKSLADVESQVSAQNKEKDTVLGRLALLQEERDKLITEMDRSLL
  ENQSLSSSCESLKLALEGLTEDKEKLVKEIESLKSSKIAESTEWQEKHKELQKEYEILLQ
  SYENVSNEAERIQHVVEAVRQEKQELYGKLRSTEANKKETEKQLQEAEQEMEEMKEKMRK
  FAKSKQQKILELEEENDRLRAEVHPAGDTAKECMETLLSSNASMKEELERVKMEYETLSK
  KFQSLMSEKDSLSEEVQDLKHQIEGNVSKQANLEATEKHDNQTNVTEEGTQSIPGETEEQ
  DSLSMSTRPTCSESVPSAKSANPAVSKDFSSHDEINNYLQQIDQLKERIAGLEEEKQKNK
  EFSQTLENEKNTLLSQISTKDGELKMLQEEVTKMNLLNQQIQEELSRVTKLKETAEEEKD
  DLEERLMNQLAELNGSIGNYCQDVTDAQIKNELLESEMKNLKKCVSELEEEKQQLVKEKT
  KVESEIRKEYLEKIQGAQKEPGNKSHAKELQELLKEKQQEVKQLQKDCIRYQEKISALER
  TVKALEFVQTESQKDLEITKENLAQAVEHRKKAQAELASFKVLLDDTQSEAARVLADNLK
  LKKELQSNKESVKSQMKQKDEDLERRLEQAEEKHLKEKKNMQEKLDALRREKVHLEETIG
  EIQVTLNKKDKEVQQLQENLDSTVTQLAAFTKSMSSLQDDRDRVIDEAKKWERKFSDAIQ
  SKEEEIRLKEDNCSVLKDQLRQMSIHMEELKINISRLEHDKQIWESKAQTEVQLQQKVCD
  TLQGENKELLSQLEETRHLYHSSQNELAKLESELKSLKDQLTDLSNSLEKCKEQKGNLEG
  IIRQQEADIQNSKFSYEQLETDLQASRELTSRLHEEINMKEQKIISLLSGKEEAIQVAIA
  ELRQQHDKEIKELENLLSQEEEENIVLEEENKKAVDKTNQLMETLKTIKKENIQQKAQLD
  SFVKSMSSLQNDRDRIVGDYQQLEERHLSIILEKDQLIQEAAAENNKLKEEIRGLRSHMD
  DLNSENAKLDAELIQYREDLNQVITIKDSQQKQLLEVQLQQNKELENKYAKLEEKLKESE
  EANEDLRRSFNALQEEKQDLSKEIESLKVSISQLTRQVTALQEEGTLGLYHAQLKVKEEE
  VHRLSALFSSSQKRIAELEEELVCVQKEAAKKVGEIEDKLKKELKHLHHDAGIMRNETET
  AEERVAELARDLVEMEQKLLMVTKENKGLTAQIQSFGRSMSSLQNSRDHANEELDELKRK
  YDASLKELAQLKEQGLLNRERDALLSETAFSMNSTEENSLSHLEKLNQQLLSKDEQLLHL
  SSQLEDSYNQVQSFSKAMASLQNERDHLWNELEKFRKSEEGKQRSAAQPSTSPAEVQSLK
  KAMSSLQNDRDRLLKELKNLQQQYLQINQEITELHPLKAQLQEYQDKTKAFQIMQEELRQ
  ENLSWQHELHQLRMEKSSWEIHERRMKEQYLMAISDKDQQLSHLQNLIRELRSSSSQTQP
  LKVQYQRQASPETSASPDGSQNLVYETELLRTQLNDSLKEIHQKELRIQQLNSNFSQLLE
  EKNTLSIQLCDTSQSLRENQQHYGDLLNHCAVLEKQVQELQAGPLNIDVAPGAPQEKNGV
  HRKSDPEELREPQQSFSEAQQQLCNTRQEVNELRKLLEEERDQRVAAENALSVAEEQIRR
  LEHSEWDSSRTPIIGSCGTQEQALLIDLTSNSCRRTRSGVGWKRVLRSLCHSRTRVPLLA
  AIYFLMIHVLLILCFTGHL
• Function: May participate in forming intercisternal cross-bridges of the Golgi complex.
• Reactome Pathway:
  COPI-mediated anterograde transport (R-HSA-6807878)
  Signaling by FLT3 fusion proteins (R-HSA-9703465)
  Golgi Associated Vesicle Biogenesis (R-HSA-432722)

Molecular Interaction Atlas (MIA) of This DOT

19 Disease(s) Related to This DOT

Disease Name	Disease ID	Evidence Level	Mode of Inheritance	REF
Nephropathy	DISXWP4P	Definitive	Biomarker	[1]
Non-insulin dependent diabetes	DISK1O5Z	Definitive	Biomarker	[2]
Advanced cancer	DISAT1Z9	Strong	Genetic Variation	[3]
Arteriosclerosis	DISK5QGC	Strong	Biomarker	[4]
Atherosclerosis	DISMN9J3	Strong	Biomarker	[4]
Cardiac failure	DISDC067	Strong	Biomarker	[5]
Congestive heart failure	DIS32MEA	Strong	Biomarker	[5]
HIV infectious disease	DISO97HC	Strong	Biomarker	[6]
Morquio syndrome	DIS2Y2P2	Strong	Altered Expression	[7]
Neoplasm	DISZKGEW	Strong	Genetic Variation	[3]
Obesity	DIS47Y1K	Strong	Biomarker	[8]
Osteochondrodysplasia	DIS9SPWW	Strong	Altered Expression	[7]
Red-green color blindness	DISV3ZVU	Strong	Genetic Variation	[9]
Gingivitis	DISC8RMX	moderate	Biomarker	[10]
Hepatocellular carcinoma	DIS0J828	moderate	Genetic Variation	[11]
Stroke	DISX6UHX	moderate	Genetic Variation	[12]
Cleft palate	DIS6G5TF	Limited	Genetic Variation	[13]
Emery-Dreifuss muscular dystrophy	DISYTPR5	Limited	Genetic Variation	[14]
Isolated cleft palate	DISV80CD	Limited	Genetic Variation	[13]

14 Drug(s) Affected the Gene/Protein Processing of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Ciclosporin	DMAZJFX	Approved	Ciclosporin increases the expression of Golgin subfamily B member 1 (GOLGB1).	[15]
Acetaminophen	DMUIE76	Approved	Acetaminophen increases the expression of Golgin subfamily B member 1 (GOLGB1).	[16]
Doxorubicin	DMVP5YE	Approved	Doxorubicin increases the expression of Golgin subfamily B member 1 (GOLGB1).	[17]
Ivermectin	DMDBX5F	Approved	Ivermectin decreases the expression of Golgin subfamily B member 1 (GOLGB1).	[18]
Marinol	DM70IK5	Approved	Marinol increases the expression of Golgin subfamily B member 1 (GOLGB1).	[19]
Diethylstilbestrol	DMN3UXQ	Approved	Diethylstilbestrol decreases the expression of Golgin subfamily B member 1 (GOLGB1).	[20]
Clozapine	DMFC71L	Approved	Clozapine increases the expression of Golgin subfamily B member 1 (GOLGB1).	[21]
Clorgyline	DMCEUJD	Approved	Clorgyline increases the expression of Golgin subfamily B member 1 (GOLGB1).	[22]
Urethane	DM7NSI0	Phase 4	Urethane increases the expression of Golgin subfamily B member 1 (GOLGB1).	[23]
Dihydrotestosterone	DM3S8XC	Phase 4	Dihydrotestosterone increases the expression of Golgin subfamily B member 1 (GOLGB1).	[24]
GSK2110183	DMZHB37	Phase 2	GSK2110183 increases the expression of Golgin subfamily B member 1 (GOLGB1).	[26]
PMID28460551-Compound-2	DM4DOUB	Patented	PMID28460551-Compound-2 increases the expression of Golgin subfamily B member 1 (GOLGB1).	[27]
Bisphenol A	DM2ZLD7	Investigative	Bisphenol A increases the expression of Golgin subfamily B member 1 (GOLGB1).	[29]
Formaldehyde	DM7Q6M0	Investigative	Formaldehyde increases the expression of Golgin subfamily B member 1 (GOLGB1).	[30]

1 Drug(s) Affected the Protein Interaction/Cellular Processes of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
DNCB	DMDTVYC	Phase 2	DNCB affects the binding of Golgin subfamily B member 1 (GOLGB1).	[25]

1 Drug(s) Affected the Post-Translational Modifications of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
PMID28870136-Compound-52	DMFDERP	Patented	PMID28870136-Compound-52 affects the phosphorylation of Golgin subfamily B member 1 (GOLGB1).	[28]

References

• [1] Apolipoprotein M: Research progress, regulation and metabolic functions (Review).Mol Med Rep. 2015 Aug;12(2):1617-24. doi: 10.3892/mmr.2015.3658. Epub 2015 Apr 22.
• [2] Comparison of Great Curvature Plication with Duodenal-Jejunal Bypass (GCP-DJB) and Sleeve Gastrectomy (SG) on Metabolic Indices and Gut Hormones in Type 2 Diabetes Mellitus Rats.Obes Surg. 2018 Dec;28(12):4014-4021. doi: 10.1007/s11695-018-3459-6.
• [3] Gene polymorphisms of folate metabolizing enzymes and the risk of gastric cancer.Cancer Lett. 2007 Jun 28;251(2):228-36. doi: 10.1016/j.canlet.2006.11.021. Epub 2007 Jan 8.
• [4] Polymorphisms in three genes are associated with hemorrhagic stroke.Brain Behav. 2015 Oct 1;5(11):e00395. doi: 10.1002/brb3.395. eCollection 2015 Nov.
• [5] Cardiac overexpression of the norepinephrine transporter uptake-1 results in marked improvement of heart failure.Circ Res. 2005 Oct 28;97(9):928-36. doi: 10.1161/01.RES.0000186685.46829.E5. Epub 2005 Sep 15.
• [6] Macrogolgin--a new 376 kD Golgi complex outer membrane protein as target of antibodies in patients with rheumatic diseases and HIV infections.J Autoimmun. 1994 Feb;7(1):67-91. doi: 10.1006/jaut.1994.1006.
• [7] Giantin is required for coordinated production of aggrecan, link protein and type XI collagen during chondrogenesis.Biochem Biophys Res Commun. 2018 May 15;499(3):459-465. doi: 10.1016/j.bbrc.2018.03.163. Epub 2018 Mar 27.
• [8] Greater Curvature Plication with Duodenal-Jejunal Bypass: a Novel Metabolic Surgery for Type 2 Diabetes Mellitus.Obes Surg. 2018 Jun;28(6):1595-1601. doi: 10.1007/s11695-017-3057-z.
• [9] A contiguous, 3-Mb physical map of Xq28 extending from the colorblindness locus to DXS15.Am J Hum Genet. 1989 Dec;45(6):873-82.
• [10] The effect of nonsurgical periodontal treatment on gingival crevicular fluid stress hormone levels: A prospective study.Oral Dis. 2019 Jan;25(1):250-257. doi: 10.1111/odi.12973. Epub 2018 Sep 27.
• [11] Mutations acquired by hepatocellular carcinoma recurrence give rise to an aggressive phenotype.Oncotarget. 2017 Apr 4;8(14):22903-22916. doi: 10.18632/oncotarget.14248.
• [12] Genetic mapping and exome sequencing identify 2 mutations associated with stroke protection in pediatric patients with sickle cell anemia.Blood. 2013 Apr 18;121(16):3237-45. doi: 10.1182/blood-2012-10-464156. Epub 2013 Feb 19.
• [13] Association between GOLGB1 tag-polymorphisms and nonsyndromic cleft palate only in the Brazilian population.Ann Hum Genet. 2018 Jul;82(4):227-231. doi: 10.1111/ahg.12242. Epub 2018 Feb 12.
• [14] Assignment of Emery-Dreifuss muscular dystrophy to the distal region of Xq28: the results of a collaborative study.Am J Hum Genet. 1991 Mar;48(3):468-80.
• [15] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [16] Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
• [17] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [18] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [19] JunD is involved in the antiproliferative effect of Delta9-tetrahydrocannabinol on human breast cancer cells. Oncogene. 2008 Aug 28;27(37):5033-44.
• [20] Identification of biomarkers and outcomes of endocrine disruption in human ovarian cortex using In Vitro Models. Toxicology. 2023 Feb;485:153425. doi: 10.1016/j.tox.2023.153425. Epub 2023 Jan 5.
• [21] Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
• [22] Anti-oncogenic and pro-differentiation effects of clorgyline, a monoamine oxidase A inhibitor, on high grade prostate cancer cells. BMC Med Genomics. 2009 Aug 20;2:55. doi: 10.1186/1755-8794-2-55.
• [23] Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
• [24] LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4179-E4188.
• [25] Proteomic analysis of the cellular response to a potent sensitiser unveils the dynamics of haptenation in living cells. Toxicology. 2020 Dec 1;445:152603. doi: 10.1016/j.tox.2020.152603. Epub 2020 Sep 28.
• [26] Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells. Cancer Med. 2017 Nov;6(11):2646-2659. doi: 10.1002/cam4.1179. Epub 2017 Sep 27.
• [27] Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
• [28] Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
• [29] Bisphenol A induces DSB-ATM-p53 signaling leading to cell cycle arrest, senescence, autophagy, stress response, and estrogen release in human fetal lung fibroblasts. Arch Toxicol. 2018 Apr;92(4):1453-1469.
• [30] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.